This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT) in patients with acute coronary syndrome (ACS). This benefit consists of a significant bleeding reduction (3.6% vs. 7.6%, P < 0.001), without compromising ischemic events (4.3% vs. 4.4%, P = 0.84). The latter, however, could be seen as<a href="https://solaci.org/en/2021/08/10/the-role-of-aspirin-after-the-twilight-acs/" title="Read more" >...</a>
In healthy adults, two doses of the NVX-CoV2373 (Novavax) vaccine has an efficacy of almost 90% against SARS-CoV-2 infection in all severity types. Furthermore, it has proven to be effective against the alpha variant (B.1.1.7). The Novavax vaccine is a recombinant nanoparticle containing full-length spike glycoprotein. It had already been shown to be safe and<a href="https://solaci.org/en/2021/07/16/efficacy-of-the-novavax-vaccine-against-covid-19-nanoparticle-technology-to-the-test/" title="Read more" >...</a>
Here is the third Fellow’s Corner clinical case to keep discussing and learning alongside the entire community of hemodynamics fellows in Latin America. In this instance, we will present a case of True Bifurcation Lesion: Which Strategy Should We Use? Content 1- Case Presentation 2- Case Resolution 3- Expert Commentary Authors: Dr. Carlos Fava (ARG)<a href="https://solaci.org/en/2021/07/05/the-fellows-corner-3rd-clinical-case-true-bifurcation-lesion-which-strategy-should-we-use/" title="Read more" >...</a>
Promising fast subcutaneous administration and a quick and potent antiplatelet effect, here comes a novel glycoprotein IIb/IIa inhibitor called RUC-4. This novel drug was tested in the CELEBRATE-02 study, presented at EuroPCR 2021 and simultaneously published in EuroIntervention. The mean platelet inhibition begins 15 minutes after injection and increases with each of the three tested doses<a href="https://solaci.org/en/2021/05/26/europcr-2021-celebrate-02-novel-glycoprotein-iib-iiia-inhibitor-for-st-segment-elevation-infarction/" title="Read more" >...</a>
01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration. Read more HERE 02- Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports This is one of the<a href="https://solaci.org/en/2021/05/07/the-most-read-scientific-articles-on-interventional-cardiology-of-april/" title="Read more" >...</a>
Acute kidney injury after transcatheter aortic valve replacement (TAVR) is a well-known adverse event for all interventional cardiologists. However, it has been understudied: only small observational research has been conducted, showing too wide incidence rates. This research included all patients who underwent TAVR in the USA between 2016 and 2018, totaling over 100,000 patients. All subjects<a href="https://solaci.org/en/2021/05/03/incidence-predictors-and-results-of-acute-kidney-injury-in-patients-undergoing-tavr/" title="Read more" >...</a>
12 weeks prior the ORBITA randomization, medical therapy optimization of all antianginal medication was achieved. Most importantly, optimization was well tolerated by all patients, with scarce adverse effects leading to therapy termination. In clinical practice, there is skepticism towards achieving maximal dosage with a cost-effective therapy, good tolerance, adherence, and no drug-drug interaction. The ORBITA<a href="https://solaci.org/en/2021/03/09/medical-therapy-optimization-achieved-prior-clinical-trial/" title="Read more" >...</a>
In this selection, we summarize for you the most important scientific news of 2020 in the field of pharmacology. 01- Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to the COLCOT trial, originally presented at the<a href="https://solaci.org/en/2020/12/17/the-most-relevant-articles-in-pharmacology-in-2020/" title="Read more" >...</a>
01- Ticagrelor or Prasugrel in ST Elevation MI In patients undergoing ST elevation acute myocardial infarction (STEMI) receiving primary PCI, no significative differences between prasugrel and ticagrelor were found. However, the latter was associated to a significantly higher number of repeat MI when considered separately. Read more HERE 02- Number of Hours of Sleep and<a href="https://solaci.org/en/2020/12/02/the-most-read-articles-in-interventional-cardiology/" title="Read more" >...</a>
High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic clopidogrel do not see a benefit in protection against periprocedural events and instead see increased costs and minor bleeding rate. These are the outcomes of the ALPHEUS study presented at AHA 2020 simultaneously published in the Lancet. Ticagrelor<a href="https://solaci.org/en/2020/11/20/aha-2020-clopidogrel-resists-as-the-best-option-in-elective-patients/" title="Read more" >...</a>